Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders

Interest in serotonergic psychedelics has resurged in recent years as neuroimaging and neuroscience advances offer new ways to study brain circuits implicated in psychiatric disorders. The authors describe a context in which default mode network (DMN) hyperconnectivity, particularly involving subgenual and pregenual cingulate regions, has been linked to depressive rumination and illness duration, and they note that diverse rapid-acting interventions (for example, electroconvulsive therapy, ketamine, transcranial magnetic stimulation) may share effects on dysfunctional network dynamics. Psilocybin, a classic 5-HT agonist, is proposed as both a probe of brain function and a potential therapeutic agent capable of disrupting pathological network hubs and enabling healthier reconnection patterns after the acute drug effect subsides. This review aims to synthesize the pharmacokinetic and pharmacodynamic properties of psilocybin together with the clinical trial evidence available through 31 December 2016 for psilocybin-assisted therapy in psychiatric indications related to anxiety, depression, and substance use. Thomas and colleagues therefore set out to evaluate efficacy signals, safety issues, and gaps in the current evidence base to inform whether further robust clinical trials are warranted.

The authors performed a targeted literature review using PubMed. For clinical evidence they searched for articles classified as "Clinical Trial" on the topic of "psilocybin and psychiatry" up to 31 December 2016. Additional PubMed searches using the terms "psilocybin," "pharmacokinetics," and "pharmacodynamics" were used to assemble background information about the drug's behaviour and mechanism. The extracted text does not report further details such as additional databases searched, formal eligibility criteria, or a PRISMA-style flow diagram. No formal meta-analytic methods, risk-of-bias assessment approach, or quantitative pooling strategy are described in the extracted text. Instead, the review summarises pharmacokinetic and pharmacodynamic findings from human and in vitro studies and narratively reports results from seven clinical trials addressing anxiety, depression, obsessive-compulsive disorder (OCD), alcohol dependence, and tobacco addiction. Where available, the authors report primary outcomes, effect sizes, correlations with subjective experience measures, and adverse events as presented in the original trials.

Pharmacokinetics: Psilocybin is rapidly dephosphorylated to the active metabolite psilocin in the intestinal mucosa. The extracted text reports evidence of a first-pass effect, detectable plasma psilocin within 20–90 minutes after oral dosing, and a bioavailability estimate of about 52.7% after 10–20 mg oral psilocybin. Reported terminal elimination half-lives for psilocin are heterogeneous: about 74 minutes after intravenous psilocybin administration in one study and 135–163 minutes after oral dosing in other studies. Psilocin undergoes glucuronidation (notably via UGT1A10 in the gut and UGT1A9 in liver) and is partly renally excreted; urine levels typically fall below the lower limit of quantitation within 24 hours. Pharmacodynamics: The psychological and physiological effects of psilocybin are attributed primarily to agonism at the 5-HT2A receptor, with reported binding affinity (Ki) of approximately 6 nM for 5-HT2A versus lower affinity at 5-HT1A (Ki ≈ 190 nM). Antagonism with ketanserin attenuated subjective effects on standard altered-states questionnaires and cognitive/physiological measures, supporting a 5-HT2A-mediated mechanism. The review notes high cortical expression of 5-HT2A receptors on deep-layer pyramidal neurons and discusses proposed downstream signalling (PLC/PKC and PLA2 pathways), potential effects on thalamic gating and cortical oscillatory power, and peripheral 5-HT2A-mediated vascular effects—hence routine cardiovascular monitoring in trials. Cancer-related anxiety and depression trials: Seven clinical trials are summarised overall; among them, three randomised, double-blind crossover trials in patients with cancer-related anxiety or depression are described. A 12-participant crossover trial compared 0.2 mg/kg psilocybin with niacin placebo and reported reductions in Beck Depression Inventory (BDI) scores at six months (mean Δ≈−9, p = 0.03) and reductions in trait anxiety at one and three months. A 29-participant crossover (0.3 mg/kg vs niacin) found significant improvements across multiple scales at seven weeks post-dose 1 with large Cohen's d values (for example HAD-T Δ≈7, d = 1.36, p ≤ 0.001) and higher response/remission rates for those receiving psilocybin first (BDI response 83% vs 14%, p ≤ 0.01; BDI remission ~80% vs ~15%, p ≤ 0.01). A larger 51-participant double-blind crossover comparing high-dose (22–30 mg/70 kg) with low-dose (1–3 mg/70 kg) found substantially greater response and remission rates at five weeks for the high-dose-first group (GRID-HAMD-17 response 92% vs 32%, p < 0.001; HAM-A response 76% vs 24%, p < 0.001), with effects largely sustained at six months. Treatment‑resistant depression and other disorders: An open-label pilot in 12 participants with treatment-resistant major depressive disorder reported large reductions on the Quick Inventory of Depressive Symptoms (QIDS mean baseline 19.2, mean Δ at 1 week −11.8; Hedges' g = 3.1) and on BDI, HAM-D and STAI-T at one week and up to three months. An open-label, dose-escalation OCD study (n = 9) reported a significant main effect of time on Yale-Brown Obsessive-Compulsive Scale scores (p = 0.046) and mean YBOCS reductions 24 hours after dosing (p = 0.028), though durability was not systematically assessed. Open-label alcohol dependence (n = 10) and tobacco addiction (n = 15 completers) proof-of-concept studies reported clinically meaningful decreases in heavy drinking days (mean baseline ~35% reduced to ~9% during weeks 1–8 post-dose; mean difference −26.0, 95% CI −8.7 to −43.2) and high smoking abstinence at six months (80% biologically supported point prevalence abstinence) respectively; both studies noted correlations between greater intensity of subjective psychedelic experience (HRS, 5D-ASC, MEQ) and better outcomes. Safety and adverse events: Across trials the most common acute adverse reactions were transient elevations in systolic and diastolic blood pressure and heart rate, transient anxiety or fear during sessions, headaches, nausea, and occasional transient psychotic-like symptoms. Reported peak mean SBP values during sessions ranged into the 130–150 mm Hg range with some individuals experiencing episodic SBP > 160 mm Hg. Adverse psychological reactions typically resolved by session end and were managed with psychological support. The review notes that many trials included preparatory and supportive psychotherapy, complicating attribution of benefit to the pharmacological agent alone.

Thomas and colleagues interpret the collected evidence as promising but preliminary. They highlight large effect sizes reported in several small trials—sometimes Hedges' g > 2—and suggest that the limited number of psilocybin-assisted therapy sessions is a distinctive treatment model compared with daily pharmacotherapy. The authors emphasise that benefits in some studies were durable for months after only a few dosing sessions, and they note a consistent correlation across studies between intensity of mystical- or peak-type subjective experience and magnitude of clinical improvement. At the same time, the review stresses important limitations and uncertainties. Considerable heterogeneity existed across the small trials in patient populations (different DSM-IV diagnoses, cancer-related comorbidity), study designs (open-label vs double-blind crossover; active vs niacin or low-dose controls), dosing regimens, concomitant psychotherapy, and timing of outcome measurement. The authors point out that no trial isolated psilocybin without supportive psychotherapy, making it unclear how much clinical benefit is attributable to the drug itself versus the psychotherapeutic context. They also note that some positive findings came from open-label designs without statistical controls, limiting causal inference. In terms of safety, the researchers characterise the profile as favourable for short-term, limited exposure: most adverse events were transient cardiovascular or psychological reactions occurring during sessions and resolving thereafter. Nevertheless, the authors recommend continued monitoring and standardised safety procedures in future trials. They conclude that larger, methodologically consistent randomised trials are required to replicate findings, determine optimal psychotherapy–drug combinations, clarify mechanisms linking subjective experience to outcomes, and support regulatory decisions; ongoing larger trials in alcohol and tobacco use disorders are cited as examples of this next step.

Psilocybin, a 5-HT2A agonist, shows preliminary evidence of efficacy for conditions related to anxiety, depression, and substance use when administered within a structured psychotherapy-supported model that typically involves a few prolonged dosing sessions. The reviewed trials indicate rapid and sometimes durable improvements on clinician-rated and self-report symptom scales, with a safety profile dominated by transient cardiovascular and psychological effects during sessions. The authors conclude that further well‑controlled, adequately powered clinical trials with standardised methods are necessary to establish whether psilocybin-assisted therapy is sufficiently safe and effective to enter mainstream psychiatric practice and to support regulatory approval.